- Home
- SONO vs MESO Comparison
SONO vs MESO Comparison
Compare SONO & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONO
- MESO
- Stock Information
- Founded
- SONO 2002
- MESO 2004
- Country
- SONO United States
- MESO Australia
- Employees
- SONO N/A
- MESO N/A
- Industry
- SONO Consumer Electronics/Video Chains
- MESO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SONO Consumer Discretionary
- MESO Health Care
- Exchange
- SONO Nasdaq
- MESO Nasdaq
- Market Cap
- SONO 1.2B
- MESO 1.3B
- IPO Year
- SONO 2018
- MESO N/A
- Fundamental
- Price
- SONO $10.62
- MESO $10.92
- Analyst Decision
- SONO Buy
- MESO Buy
- Analyst Count
- SONO 3
- MESO 4
- Target Price
- SONO $13.00
- MESO $18.00
- AVG Volume (30 Days)
- SONO 1.6M
- MESO 195.7K
- Earning Date
- SONO 08-06-2025
- MESO 02-26-2025
- Dividend Yield
- SONO N/A
- MESO N/A
- EPS Growth
- SONO N/A
- MESO N/A
- EPS
- SONO N/A
- MESO N/A
- Revenue
- SONO $1,463,138,000.00
- MESO $5,670,000.00
- Revenue This Year
- SONO N/A
- MESO $178.09
- Revenue Next Year
- SONO $3.27
- MESO $305.06
- P/E Ratio
- SONO N/A
- MESO N/A
- Revenue Growth
- SONO N/A
- MESO N/A
- 52 Week Low
- SONO $7.63
- MESO $5.78
- 52 Week High
- SONO $15.89
- MESO $22.00
- Technical
- Relative Strength Index (RSI)
- SONO 55.36
- MESO 46.62
- Support Level
- SONO $9.65
- MESO $9.88
- Resistance Level
- SONO $10.88
- MESO $12.37
- Average True Range (ATR)
- SONO 0.38
- MESO 0.42
- MACD
- SONO 0.03
- MESO -0.11
- Stochastic Oscillator
- SONO 71.54
- MESO 31.23
About SONO Sonos Inc.
Sonos Inc is engaged in providing home sound systems. The company's product profile includes speaker sets and other accessories like boost, mounts, stands, and cables and networking. Geographically, the company operates in the Americas, Europe, the Middle East and Africa and the Asia Pacific. Generating a majority of its revenue from the Americas.
About MESO Mesoblast Limited
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.